HUANG Long, LIU An-wen, MEI Shi-qi. Osimertinib Plus Chemotherapy in the First-Line Treatment of EGFR-Mutant Advanced Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2024, 24(1): 26-31. DOI: 10.12019/j.issn.1671-5144.2024.01.005
|
Citation:
|
HUANG Long, LIU An-wen, MEI Shi-qi. Osimertinib Plus Chemotherapy in the First-Line Treatment of EGFR-Mutant Advanced Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2024, 24(1): 26-31. DOI: 10.12019/j.issn.1671-5144.2024.01.005
|
HUANG Long, LIU An-wen, MEI Shi-qi. Osimertinib Plus Chemotherapy in the First-Line Treatment of EGFR-Mutant Advanced Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2024, 24(1): 26-31. DOI: 10.12019/j.issn.1671-5144.2024.01.005
|
Citation:
|
HUANG Long, LIU An-wen, MEI Shi-qi. Osimertinib Plus Chemotherapy in the First-Line Treatment of EGFR-Mutant Advanced Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2024, 24(1): 26-31. DOI: 10.12019/j.issn.1671-5144.2024.01.005
|
DownLoad: